Prolyl oligopeptidase inhibition-induced growth arrest of human gastric cancer cells

Biochemical and Biophysical Research Communications

Volumn 443, Issue 1, 2014, Pages 91-96

  Suzuki, Kanayo ^a   Sakaguchi, Minoru ^a   Tanaka, Satoshi ^a   Yoshimoto, Tadashi ^b   Takaoka, Masanori ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

Author keywords

Cell cycle arrest; Human gastric cancer cells; Prolyl oligopeptidase; Quiescent G0 state; SUAM 14746

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; PROLINE DERIVATIVE; PROLYL ENDOPEPTIDASE; PROTEIN P53; THIAZOLIDINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; STOMACH CANCER;

CELL CYCLE ARREST; HUMAN GASTRIC CANCER CELLS; PROLYL OLIGOPEPTIDASE; QUIESCENT G(0) STATE; SUAM-14746;

CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; HUMANS; PROLINE; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; STOMACH NEOPLASMS; THIAZOLIDINES;

EID: 84890856075     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.051     Document Type: Article

References (30)

1. Yoshimoto T., Ogita K., Walter R., Koida M., Tsuru D. Post-proline cleaving enzyme; synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man. Biochim. Biophys. Acta 1979, 569:184-192.
2. Myöhänen T.T., García-Horsman J.A., Tenorio-Laranga J., Männistö P.T. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J. Histochem. Cytochem. 2009, 57:831-848.
3. Yoshimoto T., Kado K., Matsubara F., Koriyama N., Kaneto H., Tsuru D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J. Pharmacobiodyn. 1987, 10:730-735.
4. Cunningham D.F., O'Connor B. Proline specific peptidases. Biochim. Biophys. Acta 1997, 1343:160-186.
5. Moreno-Baylach M.J., Puttonen K.A., Tenorio-Laranga J., Venäläinen J.I., Storvik M., Forsberg M.M., García-Horsman J.A. Prolyl endopeptidase is involved in cellular signaling in human neuroblastoma SH-SY5Y cells. Neurosignals 2011, 19:97-109.
6. Schulz I., Zeitschel U., Rudolph T., Ruiz-Carrillo D., Rahfeld J.U., Gerhartz B., Bigl V., Demuth H.U., Rossner S. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J. Neurochem. 2005, 94:970-979.
7. Ishino T., Ohtsuki S., Natori S. cDNA cloning of mouse prolyl endopeptidase and its involvement in DNA synthesis by Swiss 3T3 cells. J. Biochem. 1998, 123:540-545.
8. Šedo A., Kfepela E., Kasafǐrek E. Dipeptidyl peptidase IV, prolyl endopeptidase and cathepsin B activities in primary human lung tumours and lung parenchyma. J. Cancer Res. Clin. Oncol. 1991, 117:249-253.
9. Goossens F., De Meester I., Vanhoof G., Scharpe S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur. J. Clin. Chem. Clin. Biochem. 1996, 34:17-22.
10. Myöhänen T.T., Venäläinen J.I., Garcia-Horsman J.A., Piltonen M., Männisto P.T. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem. Cell Biol. 2008, 130:993-1003.
11. Sakaguchi M., Matsuda T., Matsumura E., Yoshimoto T., Takaoka M. Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line. Biochem. Biophys. Res. Commun. 2011, 409:693-698.
12. Prives C., Hall P.A. The p53 pathway. J. Pathol. 1999, 187:112-126.
13. William R.T., George R.S. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
14. Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O., Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M. Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem. Biophys. Res. Commun. 1992, 182:215-223.
15. Tsuru D., Yoshimoto T., Koriyama N., Frukawa S. Thiazolidine derivatives as potent inhibitors specific for prolyl endopeptidase. J. Biochem. 1988, 104:580-586.
16. Wang J.Y., Yu P., Chen S., Xing H., Chen Y., Wang M., Tang K., Tian Z., Rao Q., Wang J. Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction. Mol. Oncol. 2013, 7:907-916.
17. Saito M., Tanaka T., Higuchi N., Hashimoto M. Prolyl endopeptidase-inhibiting N-prolylthiazolidine derivatives and their use as antiamnesics. Jpn. Kokai Tokkyo Koho 1989, JP 01301671-A 19891205.
18. Saito M., Hashimoto M., Kawaguchi N., Shibata H., Fukami H., Tanaka T., Higuchi N. Synthesis and inhibitory activity of acyl-peptidyl-pyrrolidine derivatives toward post-proline cleaving enzyme; a study of subsite specificity. J. Enzyme Inhib. 1991, 5:51-75.
19. Kato J.Y., Matsuoka M., Polyak K., Massagué J., Sherr C.J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994, 79:487-496.
20. Smith E.J., Leone G., DeGregori J., Jakoi L., Nevins J.R. The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol. Cell Biol. 1996, 16:6965-6976.
21. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 2000, 182:311-322.
22. Ren S., Rollins B.J. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 2004, 117:239-251.
23. Ueda Y., Watanabe S., Tei S., Saitoh N., Kuratsu J., Nakao M. High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest. Cancer Sci. 2007, 98:1893-1901.
24. Smith E.J., Leone G., Nevins J.R. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ. 1998, 9:297-303.
25. Obaya A.J., Kotenko I., Cole M.D., Sedivy J.M. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression. J. Biol. Chem. 2002, 277:31263-32269.
26. Di Daniel E., Glover C.P., Grot E., Chan M.K., Sanderson T.H., White J.H., Ellis C.L., Gallagher K.T., Uney J., Thomas J., Maycox P.R., Mudge A.W. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol. Cell Neurosci. 2009, 41:373-382.
27. Myöhänen T.T., Hannula M.J., Van Elzen R., Gerard M., Van Der Veken P., García-Horsman J.A., Baekelandt V., Männistö P.T., Lambeir A.M. A prolyl oligopeptidase inhibitor, KYP-2047, reduces a-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br. J. Pharmacol. 2012, 166:1097-1113.
28. Matsuda T., Sakaguchi M., Tanaka S., Yoshimoto T., Takaoka M. Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death. Int. J. Biochem. Cell Biol. 2013, 45:850-857.
29. Sundararaj K.P., Wood R.E., Ponnusamy S., Salas A.M., Szulc Z., Bielawska A., Obeid L.M., Hannun Y.A., Ogretmen B. Rapid shortening of telomere length in response to ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 2004, 279:6152-6162.
30. Schmitz H.D. Reversible nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase upon serum depletion. Eur. J. Cell Biol. 2001, 80:419-427.